This plain language summary published in Future Oncology reports the findings of a recent review looking at the background and studies of different treatments for NRG1 fusion-positive cancers.
Read the summary here.
The original article on which this summary is based is called ‘NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents’ and was originally published in the journal Annals of Oncology The original article can be read here.